KANGSTEM BIOTECH Co., Ltd.
KKRX:2177301,834.00
KRW
-57.00
(-3.01%)
ISIN
KR7217730001
Return %
Stock
S&P 500
1Y
30.07
14.20
3Y
48.46
81.12
5Y
-39.46
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jong-Chun Na
- Full Time Employees
- 86
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Dec 21, 2015
- Website
- kangstem.com
- Similar Companies
- Business
- KANGSTEM BIOTECH Co., Ltd. is a South Korea-based biotechnology company engaged in the research, development, and commercialization of allogeneic umbilical cord blood-derived mesenchymal stem cell therapies, organoid models, contract development and manufacturing organization (CDMO) services, and advanced cosmeceuticals. Founded in October 2010 and headquartered in Seoul, South Korea, the company operates across four primary business segments: Stem Cell Therapeutics, Organoid Platforms, CDMO Services, and Health & Beauty. In its Stem Cell Therapeutics segment, the company develops stem cell drug candidates targeting degenerative, inflammatory, and intractable disorders, comprising OSCA (also known as FureStem-OA Kit Inj.), an injectable stem cell and medical device convergence therapy developed for cartilage regeneration and fundamental treatment of knee osteoarthritis; FureStem-AD, an umbilical cord blood-derived mesenchymal stem cell candidate indicated for moderate-to-severe atopic dermatitis; FureStem-RA, an investigational stem cell therapy designed for rheumatoid arthritis; and FureStem-CD, a clinical candidate targeting Crohn's disease. In its Organoid Platforms segment, the company produces high-fidelity, three-dimensional human tissue models, including human skin organoids, functional hair follicle organoids, and pancreatic islet organoids used for disease modeling, drug candidate discovery, and dermatological efficacy and toxicity testing as animal-free alternatives. In its CDMO Services segment, Kangstem Biotech provides biopharmaceutical manufacturing services utilizing its current Good Manufacturing Practice (cGMP)-certified facilities, offering master and working cell banking; cell isolation and large-scale culture expansion; process and analytical development; clinical batch production; quality control testing; and specialized cell cryopreservation platform services. In its Health & Beauty segment, the company manufactures and markets functional bio-cosmetics under the proprietary brand GD11, offering anti-aging and skin-rejuvenating skincare products formulated with human umbilical cord blood cell-conditioned media extract (USC1994). In recent major company developments, Kangstem Biotech has expanded its strategic alliances, clinical pipeline progression, and international regulatory certifications. The company executed an exclusive domestic license-out agreement with Yooyoung Pharma for the commercialization of its osteoarthritis candidate, OSCA, while completing patient dosing and follow-up observation in its Phase 2a clinical trial in South Korea. On the regulatory and manufacturing front, Kangstem Biotech received accreditation from Japan's Ministry of Health, Labour and Welfare (MHLW) as a certified foreign cell processing facility, enabling the provision of CDMO services and cell products to the Japanese regenerative medicine sector. Additionally, the company entered into a joint research agreement with Institut Pasteur Korea to conduct high-throughput drug screening utilizing its hair follicle organoid technology, established a collaborative partnership with Optipharm to develop next-generation diabetes treatments combining islet organoids with xenotransplantation models, and secured key patent allowances in the United States, China, and South Korea covering its cell culture, cryopreservation, and osteoarthritis therapeutic formulations.